MediciNova Valuation
| MNOV Stock | USD 1.50 0.04 2.60% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. MediciNova secures a last-minute Real Value of $3.15 per share. The latest price of the firm is $1.5. Our model forecasts the value of MediciNova from analyzing the firm fundamentals such as Shares Owned By Insiders of 2.98 %, return on equity of -0.19, and Current Valuation of 35.37 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting MediciNova's valuation include:
Price Book 1.4386 | Enterprise Value | Enterprise Value Ebitda (2.65) | Price Sales 82.8882 | Enterprise Value Revenue 38.7404 |
Undervalued
Today
Please note that MediciNova's price fluctuation is relatively risky at this time. Calculation of the real value of MediciNova is based on 3 months time horizon. Increasing MediciNova's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the MediciNova stock is determined by what a typical buyer is willing to pay for full or partial control of MediciNova. Since MediciNova is currently traded on the exchange, buyers and sellers on that exchange determine the market value of MediciNova Stock. However, MediciNova's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.5 | Real 3.15 | Target 8.33 | Hype 1.51 | Naive 1.6 |
The intrinsic value of MediciNova's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence MediciNova's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of MediciNova helps investors to forecast how MediciNova stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of MediciNova more accurately as focusing exclusively on MediciNova's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use MediciNova's intrinsic value based on its ongoing forecasts of MediciNova's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against MediciNova's closest peers.
MediciNova Cash |
|
MediciNova Valuation Trend
Analysing the historical paterns of MediciNova's enterprise value and its market capitalization is a good way to estimate and gauge the value of MediciNova over time and is usually enough for investors to make rational market timing decisions.
MediciNova Total Value Analysis
MediciNova is now estimated to have valuation of 35.37 M with market capitalization of 75.53 M, debt of 3.37 M, and cash on hands of 65.23 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the MediciNova fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
35.37 M | 75.53 M | 3.37 M | 65.23 M |
MediciNova Asset Utilization
One of the ways to look at asset utilization of MediciNova is to check how much profit was generated for every dollar of assets it reports. MediciNova secures a negative usage of assets of -0.13 %, losing $0.001297 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of MediciNova shows how discouraging it operates for each dollar spent on its assets.MediciNova Ownership Allocation
MediciNova maintains a total of 49.05 Million outstanding shares. Roughly 75.07 % of MediciNova outstanding shares are held by general public with 2.98 pct. owned by insiders and only 21.95 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.MediciNova Profitability Analysis
Net Loss for the year was (11.05 M) with profit before overhead, payroll, taxes, and interest of 0.About MediciNova Valuation
Our relative valuation model uses a comparative analysis of MediciNova. We calculate exposure to MediciNova's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of MediciNova's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 900 K | 855 K | |
| Pretax Profit Margin | (7.71) | (8.10) | |
| Operating Profit Margin | (8.91) | (9.36) | |
| Net Loss | (7.71) | (8.10) | |
| Gross Profit Margin | 0.40 | 0.23 |
MediciNova Growth Indicators
Investing in growth stocks can be very risky. If the company such as MediciNova does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 49 M |
MediciNova Current Valuation Indicators
MediciNova's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final MediciNova's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as MediciNova, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use MediciNova's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes MediciNova's worth.Additional Tools for MediciNova Stock Analysis
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.